Stockwatch: Is Mallinckrodt Deep Value Pharma?

Litigation, Depressed Sales and Bankruptcy Warning Place Stock In Value Investing Territory

The pandemic has affected generic pharmaceutical companies more than their branded brethren but accident-prone Mallinckrodt has been hit harder than most.

StockWatch_Andy-Smith_V2_1200.jpg
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Business

More from Scrip